Novare Capital Management LLC Purchases 3,134 Shares of Stryker Corporation $SYK

Novare Capital Management LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,571 shares of the medical technology company’s stock after acquiring an additional 3,134 shares during the period. Novare Capital Management LLC’s holdings in Stryker were worth $13,557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter worth about $27,000. Strive Asset Management LLC bought a new position in Stryker during the 3rd quarter worth about $30,000. CGC Financial Services LLC bought a new position in Stryker during the 4th quarter worth about $29,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker during the 3rd quarter worth about $34,000. Finally, Copia Wealth Management grew its holdings in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after acquiring an additional 69 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of Stryker stock opened at $306.74 on Friday. The company has a market capitalization of $117.59 billion, a PE ratio of 35.50, a P/E/G ratio of 1.92 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a 50-day simple moving average of $329.68 and a two-hundred day simple moving average of $351.73. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent research reports. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Canaccord Genuity Group reduced their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. UBS Group reduced their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.